Cellectis
CLLS
44 hedge funds and large institutions have $212M invested in Cellectis in 2015 Q1 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$125M |
| 2 |
JP Morgan Chase
New York
|
+$10.9M |
| 3 |
O
OrbiMed
New York
|
+$10.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.89M |
Top Sellers
CLLS Hedge Fund Activity: Q1 2015 in Review
44 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2015, worth a combined $212M.
Buyers outnumbered sellers: 44 funds opened new CLLS positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $125M.
- 44 institutional investors held Cellectis (CLLS) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $212M of Cellectis stock for Q1 2015.
- 44 funds opened new Cellectis positions in Q1 2015 and 0 closed out, a net change of +44 holders.
- The largest Cellectis buyer in Q1 2015 was Fidelity Investments, an estimated $125M added.
Based on aggregated 13F filings for Q1 2015.